Pulmatrix (PULM) Q4 2024 earnings summary

Executive summary

• Announced a merger agreement with Cullgen, expected to close in H1 2025, shifting focus to targeted protein degradation for cancer and pain indications.

• Initiated divestment of clinical assets, including Phase 2-ready migraine candidate PUR3100 and iSPERSE technology-based programs.

Financial highlights

• Revenue for 2024 was $7.8 million, up from $7.3 million in 2023, mainly due to a contract modification with Cipla.

• R&D expenses decreased to $7.2 million from $15.5 million year-over-year, reflecting the wind-down of PUR1900 and cost reductions.

• General and administrative expenses rose to $7.8 million from $6.5 million, driven by legal, professional, and one-time employee separation costs.

• Net loss narrowed to $9.6 million in 2024 from $14.1 million in 2023; loss per share improved to $(2.62) from $(3.87).

• Cash and cash equivalents stood at $9.5 million as of December 31, 2024, expected to fund operations through the merger closing.

Outlook and guidance

• Merger with Cullgen anticipated to close in the first half of 2025, subject to closing conditions.

• Pulmatrix expects its cash position to be sufficient to fund operations at least through the anticipated merger.